CA Patent

CA3245018A1 — Therapeutic compounds, formulations, and use thereof

Assigned to Tvardi Therapeutics Inc · Expires 2023-09-07 · 3y expired

What this patent protects

Provided herein are solid amorphous dispersions, compositions, and solid oral dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise a polymer excipient, and optionally a crystallization inhibiting polymer. In some instances, such com…

USPTO Abstract

Provided herein are solid amorphous dispersions, compositions, and solid oral dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise a polymer excipient, and optionally a crystallization inhibiting polymer. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or inflammatory disease/disorder.

Drugs covered by this patent

Patent Metadata

Patent number
CA3245018A1
Jurisdiction
CA
Classification
—
Expires
2023-09-07
Drug substance claim
No
Drug product claim
No
Assignee
Tvardi Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.